Evidence map›Paper›PMID 38030413›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2024

Self-Folding Macromolecular Drug Carrier for Cancer Imaging and Therapy.

Shan Gao, Yutaka Miura, Akira Sumiyoshi, Satoshi Ohno, Keisuke Ogata, Takahiro Nomoto, Makoto Matsui, Yuto Honda, Minoru Suzuki, Megumi Iiyama and 3 more

Open access · goldAbstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Self-Folding Macromolecular Drug Carrier for Cancer Imaging and Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Shan GaoLaboratory for Chemistry and Life Science, Tokyo Institute of Technology, R1-11, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.
Yutaka MiuraLaboratory for Chemistry and Life Science, Tokyo Institute of Technology, R1-11, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.ORCID 0000-0002-0506-7138
Akira SumiyoshiInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Anagawa 4-9-1, Inage, Chiba, 263-8555, Japan.
Satoshi OhnoLaboratory for Chemistry and Life Science, Tokyo Institute of Technology, R1-11, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.
Keisuke OgataLaboratory for Chemistry and Life Science, Tokyo Institute of Technology, R1-11, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.
Takahiro NomotoLaboratory for Chemistry and Life Science, Tokyo Institute of Technology, R1-11, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.
Makoto MatsuiLaboratory for Chemistry and Life Science, Tokyo Institute of Technology, R1-11, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.
Yuto HondaLaboratory for Chemistry and Life Science, Tokyo Institute of Technology, R1-11, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.
Minoru SuzukiDivision of Particle Radiation Oncology, Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University, 2-1010, Asashiro-nishi, Kumatori-cho, Sennan-gun, Osaka, 590-0494, Japan.
Megumi IiyamaInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Anagawa 4-9-1, Inage, Chiba, 263-8555, Japan.
Kensuke OsadaInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Anagawa 4-9-1, Inage, Chiba, 263-8555, Japan.
Ichio AokiInstitute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Anagawa 4-9-1, Inage, Chiba, 263-8555, Japan.
Nobuhiro NishiyamaLaboratory for Chemistry and Life Science, Tokyo Institute of Technology, R1-11, 4259 Nagatsuta-cho, Midori-ku, Yokohama, Kanagawa, 226-8503, Japan.ORCID 0000-0002-6886-9357
Tokyo Institute of Technology · JPNational Institutes for Quantum Science and Technology · JPKyoto University · JP

Funding

Japan Agency for Medical Research and Development JP23ama221221Japan Science and Technology Agency JPMJPF2202Japan Society for the Promotion of Science JP18H04163Japan Society for the Promotion of Science JP21H04966Japan Society for the Promotion of Science JP21KK0201Japan Society for the Promotion of Science JP22H00581
6 · The paper itself

Abstract

Nano-sized contrast agents (NCAs) hold potential for highly specific tumor contrast enhancement during magnetic resonance imaging. Given the quantity of contrast agents loaded into a single nano-carrier and the anticipated relaxation effects, the current molecular design approaches its limits. In this study, a novel molecular mechanism to augment the relaxation of NCAs is introduced and demonstrated. NCA formation is driven by the intramolecular self-folding of a single polymer chain that possesses systematically arranged hydrophilic and hydrophobic segments in water. Utilizing this self-folding molecular design, the relaxivity value can be elevated with minimal loading of gadolinium complexes, enabling sharp tumor imaging. Furthermore, the study reveals that this NCA can selectively accumulate into tumor tissues, offering effective anti-tumor results through gadolinium neutron capture therapy. The efficacy and versatility of this self-folding molecular design underscore its promise for cancer diagnosis and treatment.

Indexed as

Drug CarriersNeoplasmsContrast MediaGadoliniumHumansMacromolecular SubstancesContrast MediaDrug CarriersGadoliniumMacromolecular Substancescontrast agentdelivery systemmagnetic resonance imagingneutron capture therapy

Identifiers

PMID38030413
PMCPMC10870020
OpenAlexW4389153707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.